• On Target Laboratories

  Participated · Series C · Nov 2023

  On Target Laboratories develops targeted intraoperative molecular imaging agents designed to illuminate cancer during surgery, based on a near-infrared dye coupled to a targeting ligand. Its lead product, CYTALUX (pafolacianine) injection, is the company’s first commercial product and the only FDA‑approved molecular imaging agent that illuminates lung and ovarian cancer as an adjunct during surgery. CYTALUX is administered by intravenous infusion prior to surgery to help surgeons visualize and resect additional cancerous tissue. The technology traces to the work of Philip S. Low at Purdue University. The company plans to use the new financing to accelerate commercialization and expand market presence across the United States. Recent regulatory and commercialization tailwinds cited by the company include CMS granting NTAP reimbursement for CYTALUX and the clearance of Stryker’s 1788 Platform for use with CYTALUX. On Target Laboratories develops fluorescent markers and intraoperative molecular imaging technology intended to help surgeons find and remove cancerous tissue more completely. The company's lead compound is pafolacianine sodium injection, which is under priority review for ovarian cancer and is being evaluated in the Phase 3 ELUCIDATE Trial for intraoperative identification of lung cancer. The technology is based on the work of Philip S. Low, PhD at Purdue University and the company is led by President and CEO Christopher Barys. On Target plans to use recent financing to continue development and commercialization of pafolacianine sodium injection and to complete the ELUCIDATE Trial. The product is not yet approved. On Target Laboratories discovers, develops and commercializes small molecules conjugated to fluorescent dyes that target and illuminate cancerous cells and other diseased tissue for use during surgery. Its lead candidate, OTL38, is being evaluated in a Phase 3 trial in ovarian cancer and a Phase 2 trial in lung cancer and is administered intravenously before surgery to help surgeons locate lesions and margins. The company plans to use recent financing to fully develop OTL38 in ovarian and lung cancers and to introduce an additional molecule into the clinic. On Target positions its conjugates for use by surgeons and other physicians worldwide to improve diagnosis and treatment across cancers and inflammation-related disorders. Financially, the company recently completed its Series B financings, bringing the round to close to $44 million. OnTarget Laboratories has developed optical imaging technology that uses small-molecule ligands targeting receptors over-expressed on solid cancers, coupled to proprietary fluorescent imaging agents to illuminate tumors in real time during surgery. The technology was developed by Philip Low of Purdue University and initial human data were published in Nature Medicine. The company is based in the Purdue Research Park of West Lafayette. OnTarget says the probes could help surgeons remove more tumor tissue than would otherwise be possible. Management plans to use new funding to conduct further clinical trials to optimize the technology platform and to develop a pipeline of tumor-targeted molecules. The company recently received additional capital to advance that clinical development.

• Augmedics

  Participated · Series D · Jun 2023

  Augmedics develops an AR-based navigation platform (branded Xvision) combining custom hardware and software to display digitized CT scans from a surgeon’s perspective. Its system, FDA-cleared in 2019 and commercially deployed in 2020, has been used in over 4,000 procedures and is installed in more than 70 U.S. hospitals. The platform can replace fluoroscopy in some non-invasive procedures and provides continuous intraoperative spine visualization in more invasive operations. The company emphasizes purpose-built hardware optimized for surgical use rather than off-the-shelf AR gear. Management plans to use new funding to build the next generation of the platform and accelerate commercial development while remaining focused on spinal applications. It has also received inbound interest for extensions into other musculoskeletal and cranial procedures that use CT/MRI imaging. Augmedics develops the xvision Spine System, the first and only FDA‑cleared augmented reality surgical image guidance system that lets surgeons visualize 3D spinal anatomy and navigate instruments while looking directly at the patient. The company received FDA 510(k) clearance in December 2019 and began U.S. sales in the second half of 2020. By year-end 2020 the system had been used in over 250 spinal surgeries. Augmedics plans to commercialize more broadly across the U.S. and into OUS markets, pursue CE certification for Europe, develop next‑generation products, and expand to new indications. Financially, the company has raised $63 million to date following a recent $36 million Series C and an earlier $21 million Series B. Augmedics develops the xvision Spine (XVS), an augmented reality surgical image-guidance system that enables surgeons to visualize a patient’s 3D spinal anatomy during surgery. XVS is designed to let surgeons accurately navigate instruments and implants while looking directly at the patient rather than a remote screen. The company received FDA 510(k) clearance and launched XVS in the U.S. in December 2019. The system is being used in renowned hospitals and surgical centers in the U.S. In June 2020 Augmedics completed a $15M Series B round that included staff investment and SAFE conversions. Leadership cited in the article includes founder and CEO Nissan Elimelech and President and CCO Tim Murawski. Augmedics develops the ViZOR, an augmented-reality surgical visualization system that projects a 3D image of a patient’s spine onto a surgeon’s retina in real time using proprietary see-through AR optics. The ViZOR is intended initially for minimally invasive spine surgeries to reduce operative time, radiation exposure and unnecessary repeat operations or hospitalizations. Augmedics plans to complete R&D and conduct pre-clinical and clinical trials of The ViZOR, and to pursue 510(k) clearance from the U.S. FDA. Future product development includes integrating sensors to collect surgical data and applying deep learning to provide suggestions, alerts and other intraoperative assistance. The company has received industry honors and previously raised seed financing from the TerraLab incubator (an incubator of the Israeli Innovation Authority). Financially, it recently secured an $8.3 million Series A to advance regulatory and commercialization efforts.

• Invoca

  Participated · Series F · Jun 2022

  Invoca provides a cloud-based, AI-powered conversation intelligence platform that enables marketing, sales, customer experience, and eCommerce teams to understand and immediately act on information shared via conversations. Through deep integrations with top technology platforms, the company turns conversation data into automated actions to enhance digital touchpoints and human interactions, driving improved experiences, higher conversions, and increased revenue. Invoca recently introduced contact center solutions including automated quality management, agent coaching and performance, call routing, and conversational IVR, and plans to increase technology investments in these areas. The platform is used by brands such as Dish Network, Mayo Clinic, Mutual of Omaha, and 1-800-GOT-JUNK?. Led by CEO Gregg Johnson, the company intends to use new funding to accelerate product innovation through organic development and acquisitions, expand partnerships and distribution in the contact center ecosystem, and broaden geographic coverage. In June 2022 Invoca raised $83M in a Series F at a $1.1B valuation, bringing total equity financing to $184M. Invoca provides an AI-powered call tracking and conversational analytics platform that delivers real-time call and conversational insights to help marketers maximize paid media ROI and enrich customer profiles in Salesforce and Adobe Experience Cloud. Led by CEO Gregg Johnson and based in Santa Barbara, Calif., the company integrates with digital advertising, marketing technology and CRM systems to drive more revenue-generating calls and improve conversion rates. Earlier this month Invoca released Signal Discovery, a feature that uses a proprietary unsupervised machine-learning model to analyze buying conversations and surface factors affecting consumer intent, such as competitive promotional campaigns. Marketers can apply those insights in real time to boost conversion rates and improve the buying experience. The company intends to use the new funds to accelerate product development and broaden its partner ecosystem across digital advertising, martech, CRM, and affiliate marketing. The round brought total funding raised to date to $116M. Invoca offers a call-intelligence SaaS platform that measures analytics on live inbound calls and integrates those signals into marketing analytics similarly to web page views. The company has built integrations with major marketing clouds and partners, including Adobe Marketing Cloud, Salesforce, Google, Oracle and Marketo. The product is positioned for enterprise CMOs to deliver personalized customer experiences across devices and channels. Invoca is a SaaS business and has drawn strategic investor interest tied to its enterprise customer base. The company completed a $30M Series D that brings its total funding to just north of $60M. Mark Woodward joined as CEO in July; his IPO experience was cited as a reason for the hire and the new capital gives the company the option to pursue an IPO in 2017. Management also described the company as "completely self-funded," indicating operational cash strength and flexibility in deciding next steps. Invoca provides call tracking, call analytics, and custom treatment of inbound calls based on factors like location and customer status. The product integrates with sales and marketing platforms including Salesforce.com, Adobe, Kenshoo, Marketo, iCrossing, Cake, Tealium, and HasOffers. The company says it is used by more than 3,000 marketers, including Liberty Mutual Insurance, OpenTable, Answer Financial and DirecTV. Invoca reportedly saw an annual growth rate of 200 percent last year. Headquartered in Santa Barbara and formerly known as RingRevenue, the company positions itself to give enterprise marketers measurement and optimization for the phone channel. It plans to open a Bay Area office, double its workforce to more than 150 people in the next year, and increase spending on sales, marketing, and product development.

• Zerigo Health

  Participated · Series B · Oct 2021

  Zerigo Health provides an FDA-cleared, connected light therapy solution that enables Americans living with psoriasis, vitiligo, and eczema to self-administer narrowband ultraviolet B (NB-UVB) phototherapy at home or on the go. The core product is a handheld device paired with a smartphone app; prescription dosing is controlled via secure cloud-based technology and patients are remotely monitored and given personal coaching and support. The system aligns with American Academy of Dermatology guideline-recommended NB-UVB phototherapy and is designed to keep physicians and patients connected with personalized data and insights. The company said it will use the newly raised funds to expand its business reach. Zerigo raised $43M in a Series B round led by 7wireVentures. John E. Schellhorn is President and CEO, and the company is based in San Diego, California. Clarify Medical develops the Clarify Home Light Therapy System, a connected phototherapy device that uses a patient’s smartphone app to manage targeted narrowband UVB treatments. The FDA‑cleared System controls dose, frequency, and duration while monitoring dosing, adherence, patient progress, and satisfaction via cloud connectivity. Treatments are prescribed by physicians but administered at home with clinical precision, enabling remote physician oversight. The company has established Medicare coverage and says the System is now available nationally in the U.S. Clarify intends to use recent financing to commercialize the product, improve market access, and build awareness within the medical dermatology community. The announcement highlights a U.S. patient population of about 30 million people with psoriasis, vitiligo, and eczema and roughly 5,400 medical dermatologists.

• Salary.com

  Participated · Equity · Apr 2021

  Salary.com provides a SaaS compensation market data, software, and analytics platform (CompAnalyst®) that accelerates compensation workflows, delivers real-time data, and supports equitable and competitive pay decisions. Its platform serves 30,000 survey participant organizations, over 8,000 B2B software subscribers, and more than 45 million employees globally. The company has recently launched new products including the Pay Equity Reporting Toolkit and JobArchitect™, which streamlines job description management. Led by Founder & CEO Kent Plunkett, Salary.com uses its data and tools to power compensation analytics and reporting. The company intends to use new capital to accelerate innovation and expand hiring. Headquarters are in Waltham, MA.

No current team members are available.